CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

November 17th, 2009

At the AHA:  A Challenge To Uptitrate Losartan in Heart Failure

During Tuesday morning’s Late-Breaking Clinical Trials session, investigators presented results of the HEALL trial.  In this study, 3,846 patients with NYHA II-IV heart failure and LVEF ≤40% were randomized to losartan 150 mg versus 50 mg daily.  Over a median follow-up period of 4.7 years, patients in the higher-dose losartan arm had a significantly reduce rate of hospital readmission and a non-significant reduction in mortality.  The higher dose of losartan was also more likely than the lower dose to cause renal impairment, hypotension, and hyperkalemia, but not higher rates of discontinuing therapy.

Categories: General


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.